title: Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Howe
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Bergstrom
authors.forename: Bruce F
authors.initials: BF
authors.lastname: Horazdovsky
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D007334:Insulin-Like Growth Factor I